Phase II Study to Improve Sacituzumab Govitecan Tolerance With Atropine in Patients With Advanced Triple-Negative and Hormone Receptor-Positive/HER2-Negative Breast Cancer

The SATROPIN study is an international, multicenter, open-label, single-arm, phase II clinical trial to assess whether the use of prophylactic administration of atropine may prevent diarrhea in participants with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) or hormone receptor-positive/HER2-negative (HR(+)/HER2-) treated with sacituzumab govitecan.

Start Date01 Jul 2026

Sponsor / Collaborator

Medica Scientia Innovation Research SL

NCT07364370

/ Not yet recruitingNot ApplicableIIT

Myopia Progression Control Using Atropine 0.05% After Pediatric Cataract Surgery And Intraocular Lens Implantation Surgery: A Randomized Clinical Trial

Myopic shift remains a debilitating and unpredictable adverse event following pediatric cataract surgery. While research exploring peripheral myopic defocus for post-cataract surgery myopia prevention shows promising results, the use of multifocal intra-ocular lenses (IOLs) cannot be used liberally in countries with high disease burden and challenged economies due to high price and decreased availability. To date there are no studies evaluating the use of topical atropine for the management of myopic shift following pediatric cataract surgery.
The investigators aim to explore the use of 0.05% topical atropine in the prevention and management of myopic shift following pediatric cataract surgery.

Start Date01 Feb 2026

Sponsor / Collaborator

Cairo University

ChiCTR2500113604

/ Not yet recruitingNot ApplicableIIT

Clinical Study of Low-Concentration Atropine Eye Drops in Myopia Control

Start Date01 Jan 2026

Sponsor / Collaborator-

100 Clinical Results associated with Atropine Sulfate

100 Translational Medicine associated with Atropine Sulfate

100 Patents (Medical) associated with Atropine Sulfate

30,940

Literatures (Medical) associated with Atropine Sulfate

01 Apr 2026·JOURNAL OF ETHNOPHARMACOLOGY

Catha edulis and Datura stramonium mitigate oxidative stress, mitochondrial dysfunction, and cell death in an SH-SY5Y model of Parkinson's disease

Article

Author: Mogale, T ; Steenkamp, V ; de Beer, A D ; Rudolph, W J

INTRODUCTION:

Parkinson's disease (PD), the second most common neurological disorder, is often managed with medications targeting specific symptoms. Complementing conventional therapies, medicinal plants are frequently used for neurological disorders, including PD. This study evaluated the effects of crude extracts and fractions of Catha edulis (Vahl) Forssk. ex Endl. and Datura stramonium L.-psychoactive plants-on PD-related mechanisms using SH-SY5Y human neuroblastoma cells.

METHOD:

Crude extracts of C. edulis (leaves) and D. stramonium (leaf/root mixture) were prepared using dichloromethane/methanol (50/50). Fractionation was performed via C8 solid-phase extraction. Cytotoxicity and cytoprotective effects of the crude extracts and fractions against 6-hydroxydopamine-induced cytotoxicity were assessed using the sulforhodamine B assay. Mechanistic studies included reactive oxygen species (ROS) generation, mitochondrial integrity, and apoptosis assays. In silico analysis was used to assess the binding of biomarkers to dopamine receptors.

RESULTS:

Both plant extracts exhibited minimal cytotoxicity. Crude extracts and fractions (F1-F7) displayed cytoprotective effects (5.8-34.28 %). The highest ROS reduction was observed for F1 of C. edulis (1.72-fold) and F2 of D. stramonium (1.33-fold). Both extracts reduced caspase 3/7 activation and maintained mitochondrial integrity. Atropine and scopolamine showed cytoprotection with IC₅₀ values of 49.48 μM and 48.26 μM, respectively. In silico analysis indicated strong binding affinities of norephedrine and noradrenaline to dopamine D1 and D2 receptors.

CONCLUSION:

Both plant extracts preserved cell viability, reduced ROS levels, and maintained mitochondrial integrity, highlighting their potential as therapeutic agents for PD.

01 Mar 2026·VETERINARY ANAESTHESIA AND ANALGESIA

Severe bradycardia and asystole in a dog after intravenous metoclopramide injection

Article

Author: Chesnel, Mandoline ; Rolfi, Liliana

A 5-month-old English Bulldog with a history of clinically resolved bronchopneumonia was admitted for a computed tomography scan and corrective surgery for brachycephalic obstructive airway syndrome. The day of imaging and surgery, the dog did not show any signs of cardiovascular abnormalities. The dog was premedicated intravenously (IV) with maropitant (1 mg kg^-1), pantoprazole (1 mg kg^-1) and acepromazine (20 μg kg^-1). Anaesthesia was induced with alfaxalone (2 mg kg^-1) IV after 5 minutes of preoxygenation, and anaesthesia was maintained with isoflurane in oxygen [inspired fraction (FIO₂) =1]. After induction, physiological variables were unremarkable. Metoclopramide (1 mg kg^-1) was injected slowly IV, and the dog immediately developed a severe sinus bradycardia (4 beats minute^-1) followed by asystole. Cardiopulmonary resuscitation was started along with atropine (40 μg kg^-1 IV), and isoflurane discontinued. Within 1 minute, spontaneous circulation with stable haemodynamic variables was restored. Both the diagnostic and the surgical procedures were completed without further complications. The dog recovered and was discharged the same day. Rare but serious cardiac effects have been described following metoclopramide administration in humans, including bradycardia, asystole and arrhythmia. Cardiotoxicity may be linked to its clinical ability to inhibit sodium channels. To our knowledge, no metoclopramide-induced asystole has previously been reported in veterinary patients. The link between cardiac arrest and metoclopramide administration and possible predisposing factors in this case are discussed.

01 Mar 2026·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Stability of expired tropane alkaloid ampoules using HPLC-UV/CAD

Article

Author: Holzgrabe, Ulrike ; Klapper, Sylvia

Medicines often have a much longer shelf life than stated by the manufacturer. Due to the high costs of emergency stockpiling, but also due to supply shortages, an extended shelf life can offer many advantages. In this study, three injection solutions containing atropine, scopolamine and belladonna total alkaloids, respectively, manufactured between 1940 and 1960 and stored under uncontrolled conditions, were tested, to show that pharmaceutical products, containing tropane alkaloids, are significantly more stable than expected after some 80 years. To analyze the stability of the main alkaloids atropine and scopolamine, a method using charged aerosol detection (CAD) was developed and validated. CAD enables the detection of degradation products that lack a chromophore and cannot be detected using pharmacopoeial (UV) methods. For separation a SIELC Primesep 200 column (4.6 ×150 mm; 100 Å; 3 µm) and gradient elution with water, acetonitrile and formic acid were used. The results indicated a high stability of atropine, with a determined content of 101.9 % and a small amount of degradation products. Scopolamine, however, showed higher degree of degradation with a remaining content of 68 %.

115

News (Medical) associated with Atropine Sulfate

28 Jan 2026

·www.prnewswire.com

Singapore Eye Research Institute tops ScholarGPS rankings in Ophthalmology

The Institute has placed #1 in ophthalmology among all non-academic institutes, and #2 in the same field among all institutes, globally. SINGAPORE, Jan. 27, 2026 /PRNewswire/ -- The Singapore Eye Research Institute (SERI) has achieved a landmark milestone in December 2025 by securing first place among all non-academic institutes in ophthalmology, on the American scholarly analytics platform ScholarGPS, whilst also claiming second place overall among all institutes in the field globally. This is based on data from the last five years evaluated by the platform. The achievement represents a significant breakthrough for the institute, which has steadily built its translational research capabilities and international eminence in ophthalmic research and biopharmaceuticals for nearly three decades. As the research arm of the Singapore National Eye Centre (SNEC), SERI's rise to the summit of global ophthalmology research rankings since 1997 underscores Singapore's growing prominence as a hub for medical research and innovation in the Asia-Pacific region. Recognition validates SERI's research impact and mission ScholarGPS, a leading platform for tracking academic and research performance, evaluates institutions based on various metrics including research output, citation impact, and scholarly influence. SERI's exceptional performance across these indicators reflects the institute's commitment to advancing eye care through cutting-edge research and clinical excellence. Among the consistent body of quality work that contributed to this achievement are research in diabetic retinopathy, ocular surface (dry eye disease), cornea, myopia and glaucoma. Newer areas of impact also include research in artificial intelligence, digital health, and imaging. "This milestone is a testament to the dedication and expertise of our research teams, clinician-scientists, and support staff who have worked tirelessly to advance the frontiers of ophthalmology research," said Professor Jodhbir Mehta, Executive Director at SERI. "Reaching the top of the ScholarGPS rankings validates our mission to translate innovative research into better outcomes for patients with eye diseases, and we look forward to building upon this remarkable achievement in 2026." SERI's success in translational research over the years SERI's cutting-edge translational research is making a real difference for patients today. The areas of impact include new biopharmaceuticals, such as the development of Vabysmo (faricimab), which reduces the number of injections required for patients with diabetic eye diseases and age-related macular degeneration. Patients who previously needed monthly eye injections to maintain their vision can now go for injections every three to four months instead with this treatment. SERI also developed Myopine, a low-dose atropine eye drop for the treatment of childhood myopia. This treatment is now available to patients in multiple countries throughout Asia and the rest of the world. The Institute has also been credited with several device inventions. One of them is the EndoGlide, the world's first US Food and Drug Administration-approved device for advanced corneal endothelial transplant, which is commercially available worldwide. Another device is the Polarisation-Sensitive Optical Coherence Tomography which enables doctors to look at how tissues at the back of the eye affect light's properties on a microscopic level without invasive procedures. This has resulted in the development of a biomarker to track myopia progression. Since two decades ago, SERI had already been at the forefront of integrating artificial intelligence (AI) tools with eye care. Most notably, it created the Singapore Eye Lesion Analyser (SELENA+), an AI software which automatically and accurately detects diabetes-related eye diseases that could lead to blindness if left undiagnosed. Today, SELENA+ is a screening tool used in the Singapore Integrated Diabetic Retinopathy Programme, and Singapore is one of a few countries in the world to have a fully deployed AI screening tool developed by SERI and SNEC. About Singapore Eye Research Institute Established in 1997 as Singapore's national research institute for ophthalmic and vision research, the Singapore Eye Research Institute's (SERI) mission is to conduct high-impact eye research that prevents blindness, low vision and major eye diseases common to Singaporeans and Asians. Over the years, SERI has conducted landmark research projects that have led to tangible outcomes, patient benefits, and success stories. It has paved the way for significant improvements in how eye diseases are treated and prevented around the world. As the research institute of the Singapore National Eye Centre and the largest eye research institute in the Asia Pacific region, SERI collaborates with local clinical ophthalmic centres and biomedical research institutions, as well as major eye centres and research institutes globally. SERI has published an impressive array of 5,942 scientific papers and has secured external peer-reviewed competitive grants. As of December 2024, SERI's faculty has been awarded with more than 1,425 national and international prizes and filed 188 patents. Visit us at . About Singapore National Eye Centre Singapore National Eye Centre (SNEC) was incorporated in 1989 and commenced operations in 1990. It is the designated national centre within Singapore's public sector healthcare network, and spearheads and coordinates the provision of specialised ophthalmological services with emphasis on quality education and research. With 10 subspecialties in ophthalmology, SNEC has achieved rapid growth and currently manages an annual workload of 400,000 outpatient visits and over 30,000 major eye surgeries. Visit us at . SOURCE Singapore National Eye Centre; Singapore Eye Research Institute 21% more press release views with Request a Demo

Drug Approval

15 Jan 2026

·www.einpresswire.com

Mark Cuban Cost Plus Drugs and Alchem Laboratories Announce Alliance to Advance Essential Medicines

DALLAS, TX, UNITED STATES, January 15, 2026 / EINPresswire.com / -- Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) and Alchem Laboratories Corporation (Alchem) today announced the formation of a strategic alliance to develop essential medicine therapeutics, improving supply chain resiliency. Cost Plus Drugs is employing a highly automated and flexible manufacturing platform that integrates AI and machine learning for real-time quality assessment and process optimization to produce lidocaine, a widely used anesthetic, and diltiazem, a calcium channel blocker used to treat heart conditions., Alchem provided process development of these APIs for Cost Plus Drugs. Alchem has experience performing process development, scale-up, and GMP manufacturing of over 200 APIs, including the USP APIs amikacin, atropine, carboplatin, ciprofloxacin, cisplatin, dantrolene, dobutamine, dopamine, fluconazole, levofloxacin, linezolid, metronidazole, phentolamine, sulfamethoxazole, trimethoprim, and verteporfin. Under the terms of the agreement, the parties will also collaborate to supply 86 essential medicines and medical countermeasures including critical care drugs and antimicrobials. In September 2025, Alchem Laboratories and Applied Pharmaceutical Innovation (API-Canada) announced a Strategic Alliance to advance Antimicrobial and Essential Medicines Programs. This new alliance expands work under that collaboration, providing enhanced and equitable access to antimicrobial agents and essential medicines, with North American onshoring of critical therapies to support public needs. Alchem and API-Canada will initially work on lidocaine and diltiazem vial supply for Canada, as well as antimicrobials and vial manufacturing. As part of the arrangement, API-Canada will also support diltiazem and lidocaine vial supply more broadly as required by the collaborators. Both Alchem and Cost Plus Drugs maintain the flexibility to pursue funding and development pathways commensurate with project maturity and strategic alignment. About Mark Cuban Cost Plus Drugs The Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) aims to fundamentally change the way the pharmaceutical industry operates. As a public-benefit corporation, its social mission of improving public health is just as important as the bottom line. Cost Plus Drugs transparently charges a standard markup on every drug it sells. The costplusdrugs.com online pharmacy launched in January 2022 now carries over 2,300 prescription products, delivered by mail to thousands of happy customers every day. Customers can also go to participating retail pharmacies to receive Cost Plus Drugs pricing through the Team Cuban Card. Cost Plus Drugs is working with health plans, managed-care organizations, PBMs, and self-insured employers to bring these same savings to benefit plans nationwide. Learn more at www.markcubancostplusdrugcompany.com . Dr. Alex Oshmyansky, CEO Mark Cuban Cost Plus Drugs press@costplusdrugs.com About Alchem Laboratories Corporation Alchem Laboratories Corporation is a pharmaceutical development company dedicated to advancing therapies in areas of high unmet medical need, with an emphasis on accessible, high-quality essential medicines. Alchem is a subsidiary of TRON Group Inc. (OTC:TGRP). Dr. James D Talton, CEO Alchem Laboratories Corporation info@alchem.com About Applied Pharmaceutical Innovation Applied Pharmaceutical Innovation is one of Canada’s largest not-for-profit life sciences commercialization organizations. Headquartered in Edmonton, Alberta, Applied Pharmaceutical Innovation works to accelerate the development, manufacturing, and commercialization of life sciences products, and is home to Canada’s largest security of supply initiative. Jenna Bienert Applied Pharmaceutical Innovation communications@appliedpharma.ca Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

License out/in

08 Dec 2025

·eng.tshbiopharm.com

TSH Introduces Taiwan’s First Presbyopia Drug

TSH Biopharm (TW-8432) today (08/12/2025) announced a strategic collaboration with leading ophthalmic company Zhaoke Ophthalmology (6622.HK) to introduce BCSA25, an innovative therapy for presbyopia currently under review by the U.S. FDA. This product will be Taiwan’s first prescription eye drop specifically designed to relieve presbyopia symptoms. The collaboration not only strengthens TSH’s product portfolio in ophthalmology but also provides more diverse and clinically valuable treatment options for visual care in an aging society. Presbyopia is a common concern among middle-aged and older adults. According to the National Health Administration’s 2021 National Health Interview Survey, the proportion of people aged 45 and above with presbyopia in Taiwan is rising, with a prevalence rate of 65.8% among those over 651. This reflects increasing near-vision demands driven by an aging population and changing visual habits. Global studies also indicate that widespread digital lifestyles and increasing visual load have led to an earlier onset of presbyopia, expanding the market demand for new, non-surgical treatment options. The presbyopia drug BCSA25 is currently under FDA review in the United States. The product provides complementary action on two sets of iris antagonist muscles. Studies show statistically significant improvements in near vision at all time points within eight hours2, enhancing depth of focus and improving near-vision quality. BCSA25 has become an internationally recognized non-surgical treatment option for presbyopia. Sze Yuan Yang, General Manager of TSH Biopharm, stated: “Taiwan is moving toward a super-aged society, and visual health has become an important quality-of-life issue for middle-aged and older adults. The introduction of BCSA25 not only fills a gap in Taiwan’s self-paid presbyopia treatment market but also demonstrates our commitment to bringing international innovative therapies to improve patient quality of life. Through our collaboration with Zhaoke Ophthalmology, we hope to provide more Taiwanese people access to evidence-based, non-surgical presbyopia treatment options.” Dr. Li Xiaoyi (Benjamin), Chairman of the Board, Executive Director, and CEO of Zhaoke Ophthalmology, added: “BCSA25 is an important achievement in the field of presbyopia, and we are delighted to collaborate with TSH, a company deeply involved in Taiwan’s specialist healthcare sector. We believe this partnership will accelerate the clinical introduction and commercialization of the product in Taiwan and further enhance access to vision care for the aging population.” This collaboration not only expands TSH’s product depth in ophthalmology but also underscores the company’s execution capability in international partnerships and the introduction of innovative therapies. Moving forward, TSH will continue to expand its specialist treatment areas, deepen its product portfolio, and leverage robust governance and reliable development strategies to bring more innovative medical products to Taiwan. About TSH Biopharm Corporation Limited Founded in 2010, TSH Biopharm Corporation Limited (TW-8432) is a Taiwan-based pharmaceutical company committed to patient-centric care and long-term disease management. The Company specializes in chronic therapeutic areas—cardiovascular, gastrointestinal, central nervous system, and ophthalmology—delivering safe, effective, and accessible solutions that address unmet needs in daily disease control and improve quality of life. To meet evolving healthcare needs, TSH Biopharm has expanded beyond chronic-disease therapeutics into prevention and precision medicine, establishing an integrated framework that spans prevention, diagnosis, and treatment. Key initiatives—including probiotics, vaccines, and next-generation sequencing (NGS) testing—underscore the Company’s commitment to comprehensive, high-value healthcare. Driven by its vision to enhance patient quality of life and serve as a preferred strategic partner for global biomedical innovation in Asia, TSH Biopharm continues to strengthen its chronic-care leadership, accelerate technology-driven innovation, and expand across emerging Asian markets. The Company upholds strong corporate responsibility and governance standards, aiming to create long-term, sustainable impact on public health. For more information, please visit: https://www.tshbiopharm.com/ About Zhaoke Ophthalmology Limited Founded in 2017, Zhaoke Ophthalmology Limited (SEHK: 6622) is a leading ophthalmic pharmaceutical company dedicated to researching, developing, manufacturing, and commercializing therapies that address significant unmet medical needs worldwide. The company has been listed on the Main Board of the Hong Kong Stock Exchange since 29 April 2021. Zhaoke Ophthalmology has a comprehensive drug portfolio of innovative and generic treatments covering major eye diseases across both the front and the back of the eye. Currently, the company is focusing on major near-term development programs that are either in the registration stage (i.e. Cyclosporine A Ophthalmic Gel, Atropine Sulphate Eye Drops (NVK002) and Bevacizumab Intravitreal Injection (TAB014)), or in different stages in clinical trial (e.g. BCSA25, ZKY001) for the treatment of five respective major ophthalmic diseases, i.e. dry eye disease, myopia, wet AMD, presbyopia and corneal epithelial defects. Many drugs are being produced in its state-of-the-art, fully functional development and production facility in Nansha, Guangzhou, Guangdong Province. Through its ambitious growth strategy, which includes partnering with domestic and international pharmaceutical companies, Zhaoke Ophthalmology aims to become a global leader in the field of ophthalmology. For more information, please visit: www.zkoph.com

Drug Approval

100 Deals associated with Atropine Sulfate

External Link

KEGG	Wiki	ATC	Drug Bank
D02069	Atropine Sulfate	A03BA01 S01FA01	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Myopia	Australia	Aspen Pharmacare Australia Pty Ltd.	13 Sep 2021
Heart Arrest	United States	Accord Healthcare, Inc.	29 Sep 2020
Mushroom Poisoning	United States	Accord Healthcare, Inc.	29 Sep 2020
Bradycardia	United States	Fresenius Kabi USA LLC	26 Jan 2018
Amblyopia	United States	Rising Pharmaceuticals, Inc.	18 Jul 2014
Arrhythmias, Cardiac	China	Chengdu First Pharmaceutical Co. Ltd.	01 Jan 1981
Pain	China	Chengdu First Pharmaceutical Co. Ltd.	01 Jan 1981
Poisoning	China	Chengdu First Pharmaceutical Co. Ltd.	01 Jan 1981
Ophthalmoplegia	Japan	Santen Pharmaceutical Co., Ltd.	31 Mar 1970
Cycloplegia	Japan	ROHTO NITTEN Co., Ltd.	20 Jul 1968
Mydriasis	Japan	ROHTO NITTEN Co., Ltd.	20 Jul 1968
Colic	South Korea	Daewon Pharmaceutical Co., Ltd.	03 Mar 1964
Constipation	South Korea	Daewon Pharmaceutical Co., Ltd.	03 Mar 1964
Organophosphate Poisoning	South Korea	Daewon Pharmaceutical Co., Ltd.	03 Mar 1964

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Myopia, Degenerative	Phase 3	United States	Ocumension Therapeutics	01 Apr 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03949101 (Pubmed \| BMC Ophthalmol)	Phase 4	Myopia	177	1% atropine	ehbswkmepi(rshpkzdrdh) = owinjxttbe dlaatnmryl (musytpjlnv ) View more	Positive	18 Nov 2025
				0.01% atropine	whfgdkkrws(taezybcihp) = wwdranzvhf pkohrmhanw (iwjsvvcdbx ) View more
NCT03911271 (APP \| 2018-001286-16 \| ###DELETE, CTgov)	Phase 2	Myopia	97	0.1% atropine and 0.01% atropine (Loading Dose)	jspdxxpdsi(izarsypgei) = wzntwydfpc jduneskgcw (evngwvkhre, kjhkrzneja - wjjdqxjwsk) View more	-	18 Jun 2025
				0.01% atropine (Low Dose)	jspdxxpdsi(izarsypgei) = xkybztqiqp jduneskgcw (evngwvkhre, qxhuyyxxjy - fqnnritran) View more
NCT06366087 (SABER, CTgov)	Phase 1	-	46	Atropine Sulfate Ophthalmic Solution USP, 1% (Sublingual)	imdcouijdd(yohflnleij) = iarrploypk ccekqebgrs (sjxejtotkl, 23.0) View more	-	04 Apr 2025
				Atropine Sulfate Injection, USP 8 mg/20 mL (0.4 mg/mL) (Intramuscular)	imdcouijdd(yohflnleij) = tlthkzozja ccekqebgrs (sjxejtotkl, 19.0) View more
NCT06209281 (Mini-CHAMP, NEWS) Manual	Phase 3	Myopia	526	NVK002	jaunldfcwk(ymrrsrxvaj) = 达到了其主要疗效终点。 mdwppcsyqe (dlfhlxeabb ) Met View more	Positive	07 Jan 2025
				Placebo
NCT03750656 (HyTa Stent, CTgov)	Phase 4	Lower Urinary Tract Symptoms	5	Hyoscyamine (Hyoscyamine)	nffokbueri(ljcjdpfocn) = cdssigbmbu qoqqbthxrf (bsrzzbaubr, quzqjqonfb - mezdxbmuus) View more	-	03 Dec 2024
				Tamsulosin (Tamsulosin)	nffokbueri(ljcjdpfocn) = mezzwxjizk qoqqbthxrf (bsrzzbaubr, zmynuodqaq - qgbhbrbklj) View more
NCT03350620 (CHAMP, CTgov)	Phase 3	Myopia	670	NVK-002 Concentration 1 (NVK-002 Concentration 1)	evperhcerl = rjputyviap jnzpokvzry (alvizplehx, hruhrkiqyr - yhkrqgurrd) View more	-	27 Nov 2024
				NVK-002 Concentration 2 (NVK-002 Concentration 2)	evperhcerl = ccxdqxtdvm jnzpokvzry (alvizplehx, kasigicotr - uxqddghlcs) View more
NCT03942419 (CHAPERONE, GlobeNewswire) Manual	Phase 3	Myopia	252	0.01% atropine ophthalmic metered spray	myupkubsfw(zxwflcnvhs) = not significantly different jisaqqhikn (lmmmpdiyas ) View more	Negative	15 Nov 2024
				0.1% atropine ophthalmic metered spray
NCT06209320 (China CHAMP, Corporate Publications \| NEWS) Manual	Phase 3	Myopia	-	NVK002	npdhrxxdcq(wuxkvhlyyn) = NVK002滴眼液组（0.01%和0.02%剂量）对比安慰剂组在主要疗效指标上有统计学意义的显著性差异，NVK002滴眼液组优于安慰剂组，且具有剂量依赖。 ibyghdlmci (xklkeqmspn ) View more	Positive	24 Oct 2024
				Placebo
NCT03374306 (CTgov)	Not Applicable	Myopia	71	Atropine (0.01%) (Atropine 0.01%)	ghnukjlsrc(fzwidazppe) = fhvjgvkiml vdqrucsfgf (gekcyoject, 0.39) View more	-	16 Oct 2024
				Artificial tear (Artifical Tear)	ghnukjlsrc(fzwidazppe) = zqndmwnajy vdqrucsfgf (gekcyoject, 0.41) View more
NCT03334253 (Pubmed \| Optom Vis Sci)	Phase 3	Myopia \| Spondylometaphyseal Dysplasia, Axial	187	Atropine 0.01%	kgvzjtahyn(srruluxlli) = lzarinhdfj shultplvrj (zrwolekhef, 0.10 - 0.15)	-	01 Oct 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Atropine Sulfate

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation